USANA Health Sciences, Inc.
19.61-0.72 (-3.54%)
Oct 29, 4:00:02 PM EDT · NYSE · USNA · USD
Key Stats
Market Cap
358.31MP/E (TTM)
10.89Basic EPS (TTM)
1.80Dividend Yield
0%Recent Filings
8-K
8-K
USANA Q3 results miss
USANA Health Sciences reported preliminary Q3 2025 net sales of $214 million, up from $200 million last year, but operating earnings plunged to $1.2 million from $15.6 million amid a rocky rollout of its enhanced Brand Partner compensation plan and weaker Hiya sales. The effective tax rate spiked to 471%, driving a $6.5 million net loss and ($0.36) diluted EPS. Yet the plan aims to boost long-term productivity. Full-year sales now tilt toward the low end of guidance.
10-Q
Q2 FY2025 results
USANA's Q2 net sales climbed 10.8% year-over-year to $235.8M, fueled by $33.9M from the Hiya direct-to-consumer segment, while direct selling dipped 5.7% to $199.1M amid a 10.7% drop in active customers to 418,000, offset by higher average spend. Gross margin slipped to 78.7% from 81.1%, pressured by Hiya's lower margins, yet operating income held at $16.7M, down 6.3% year-over-year, with diluted EPS steady at $0.52 on 18.5M shares. Hiya, acquired in December 2024 for $206.1M cash, added $127.3M goodwill and $124.2M intangibles amortized over undisclosed lives. Cash sits at $151.3M with no line-of-credit draw from the $75M facility maturing 2030, though $27.7M share repurchases trimmed liquidity. Hiya's integration bolsters diversification. Regulatory hurdles in China shadow direct selling growth.
8-K
USANA Q2 sales grow 11%
USANA Health Sciences reported Q2 2025 net sales of $236 million, up 11% year-over-year, driven by Hiya's $34 million contribution amid a 6% sequential dip. While direct selling sales fell 6% to $199 million with active customers down 11% to 418,000, adjusted diluted EPS surged 36% to $0.74, bolstered by Hiya's profitability. The company rolled out enhanced incentives for Brand Partners and a Disney partnership for Hiya, yet direct selling faces headwinds from economic pressures. USANA reiterates full-year guidance of $920 million to $1.0 billion in sales. Risks include integration challenges and tariff impacts.
8-K
USANA secures $75M credit facility
USANA Health Sciences entered into a Third Amended and Restated Credit Agreement on June 27, 2025, with Bank of America, securing a $75 million revolving facility maturing in 2030, expandable by $200 million at the company's option. Obligations are backed by subsidiary guarantees and pledges of subsidiary stock, with interest on SOFR loans at 1.75% plus the applicable rate and base rate loans at 0% plus the applicable rate, while covenants mandate consolidated EBITDA above $80 million through mid-2026 and $100 million thereafter, alongside a funded debt to EBITDA ratio below 2.0:1. No dividend or repurchase restrictions apply, but defaults trigger acceleration and remedies. Yet liquidity remains flexible.
BFNH
BioForce Nanosciences Holdings,
0.80+0.00
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
FTLF
FitLife Brands, Inc.
19.23-0.57
GLUC
Glucose Health, Inc.
0.13+0.03
HAIN
The Hain Celestial Group, Inc.
1.31-0.04
HLF
Herbalife Ltd.
8.02-0.09
LFVN
Lifevantage Corporation
8.15-0.36
NAII
Natural Alternatives Internatio
2.81-0.05
NATR
Nature's Sunshine Products, Inc
13.42-0.43
NUS
Nu Skin Enterprises, Inc.
10.65-0.09